申请人:Merck Sharp & Dohme Corp.
公开号:US10227331B2
公开(公告)日:2019-03-12
The present invention relates to metallo-β-lactamase inhibitor compounds of Formula I: (I) and pharmaceutically acceptable salts thereof, wherein Z, RA, X1, X2 and RB are as defined herein. The present invention also relates to compositions which comprise a metallo-β-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more β-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance.
本发明涉及式 I 的金属-β-内酰胺酶抑制剂化合物: (I) 及其药学上可接受的盐,其中 Z、RA、X1、X2 和 RB 如本文所定义。本发明还涉及组合物,该组合物包含本发明的金属-β-内酰胺酶抑制剂化合物或其药学上可接受的盐,以及药学上可接受的载体,可选择与β-内酰胺抗生素和/或β-内酰胺酶抑制剂结合使用。本发明进一步涉及治疗细菌感染的方法,包括向患者施用治疗有效量的本发明化合物,与治疗有效量的一种或多种β-内酰胺类抗生素联合使用,也可选择与一种或多种β-内酰胺酶抑制剂化合物联合使用。本发明的化合物在本文所述的克服抗生素耐药性的方法中是有用的。